Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.73 |
| ▸ | NPC1 | O15118 | 6/20 | 0.73 |
| ▸ | MEN1 | O00255 | 2/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.73 |
| ▸ | CASP3 | P42574 | 1/20 | 0.63 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | HTR2C | P28335 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | GABRP | O00591 | 1/20 | 0.52 |
| ▸ | GABRD | O14764 | 1/20 | 0.52 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.52 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.52 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.52 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.52 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.52 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4241048 | 0.87 | HTR2C (0.70) | RAB9ANPC1MEN1KMT2AALDH1A1 | |
| SCHEMBL3194481 | 0.85 | RAB9A (0.79) | RAB9ANPC1MEN1KMT2ACASP3 | |
| SCHEMBL11903794 | 0.85 | RAB9A (1.00) | RAB9ANPC1MEN1KMT2ACASP3 | |
| SCHEMBL32319858 | 0.85 | RAB9A (1.00) | RAB9ANPC1MEN1KMT2ACASP3 | |
| SCHEMBL397919 | 0.81 | CFTR (0.74) | HTR2CGABRA1GABRB1GABRA5GABRA3 | |
| SCHEMBL11924590 | 0.79 | KIF20A (0.58) | RAB9ANPC1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL13042999 | 0.79 | RAB9A (0.64) | RAB9ANPC1MEN1KMT2ACASP3 | |
| SCHEMBL11924589 | 0.79 | RAB9A (0.81) | RAB9ANPC1MEN1KMT2ACASP3 | |
| SCHEMBL3721330 | 0.78 | RAB9A (0.75) | RAB9ANPC1MEN1KMT2ACASP3 | |
| SCHEMBL25920495 | 0.78 | HTR2C (0.45) | RAB9ANPC1MEN1KMT2ACASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140155626-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-06-05 | — | — | US | disclosed |
| US-20130011923-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-10 | — | — | US | disclosed |
| US-8242149-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-14 | — | — | US | disclosed |
| WO-2010139982-A1 | INDOLE DERIVATIVES FOR THE STIMULATION OF STEM CELL PROLIFERATION | THE UNIVERSITY OF SHEFFIELD (GB) | 2010-12-09 | — | — | WO | disclosed |
| EP-0931063-B3 | N-SUBSTITUTED INDOL-3-GLYOXYLAMID WITH ANTIASTHMATIC, ANTIALLERGIC AND IMMUNOSUPPRESSIVE/IMMUNOMODULATING EFFECT | ZIOPHARM ONCOLOGY INC (US) | 2009-04-08 | — | — | EP | disclosed |
| EP-0931063-B1 | N-SUBSTITUTED INDOL-3-GLYOXYLAMID WITH ANTIASTHMATIC, ANTIALLERGIC AND IMMUNOSUPPRESSIVE/IMMUNOMODULATING EFFECT | BAXTER HEALTHCARE SA (CH) | 2006-10-18 | — | — | EP | disclosed |
| US-20020161025-A1 | N-substituted indole-3glyoxylamides having anti-asthmatic, antiallergic and immunosuppressant/immuno-modulating action | ZIOPHARM ONCOLOGY, INC. | 2002-10-31 | — | — | US | disclosed |
| US-6008231-A | ANTIALLERGENS, ANTIHISTAMINES, IMMUNOSUPPRESSANTS, IMMUNOMODULATORS | ASTA MEDICA AKTIENGESELLSCHGT (DE) | 1999-12-28 | — | — | US | disclosed |
| EP-0931063-A1 | N-SUBSTITUTED INDOL-3-GLYOXYLAMID WITH ANTIASTHMATIC, ANTIALLERGIC AND IMMUNOSUPPRESSIVE/IMMUNOMODULATING EFFECT | ASTA Medica Aktiengesellschaft (DE) | 1999-07-28 | — | — | EP | disclosed |
| WO-1998009946-A1 | N-SUBSTITUTED INDOL-3-GLYOXYLAMID WITH ANTIASTHMATIC, ANTIALLERGIC AND IMMUNOSUPPRESSIVE/IMMUNOMODULATING EFFECT | ASTA MEDICA AKTIENGESELLSCHAFT (DE) | 1998-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161025-A1 | N-substituted indole-3glyoxylamides having anti-asthmatic, antiallergic and immunosuppressant/immuno-modulating action | IDO1, IDO2, INMT | RAB9A 3511/4885NPC1 4190/4885MEN1 4372/4885 |
| US-20140155626-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | RAB9A 2302/4885NPC1 29/4885MEN1 4698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.